NO304406B1 - Preparat med regulert frigivelse og kapsel omfattende dette - Google Patents
Preparat med regulert frigivelse og kapsel omfattende dette Download PDFInfo
- Publication number
- NO304406B1 NO304406B1 NO923128A NO923128A NO304406B1 NO 304406 B1 NO304406 B1 NO 304406B1 NO 923128 A NO923128 A NO 923128A NO 923128 A NO923128 A NO 923128A NO 304406 B1 NO304406 B1 NO 304406B1
- Authority
- NO
- Norway
- Prior art keywords
- controlled release
- diltiazem
- preparation according
- cores
- preparation
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title claims description 4
- 239000003405 delayed action preparation Substances 0.000 title description 3
- 238000013270 controlled release Methods 0.000 claims abstract description 22
- 238000000576 coating method Methods 0.000 claims abstract description 20
- 239000011248 coating agent Substances 0.000 claims abstract description 19
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims abstract description 19
- 229960004166 diltiazem Drugs 0.000 claims abstract description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000004014 plasticizer Substances 0.000 claims abstract description 6
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 5
- 239000004094 surface-active agent Substances 0.000 claims abstract description 4
- 239000003607 modifier Substances 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 4
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Fertilizers (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919117361A GB9117361D0 (en) | 1991-08-12 | 1991-08-12 | Oral dosage form |
| GB919122967A GB9122967D0 (en) | 1991-10-29 | 1991-10-29 | Pharmaceutical composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO923128D0 NO923128D0 (no) | 1992-08-11 |
| NO923128L NO923128L (no) | 1993-02-15 |
| NO304406B1 true NO304406B1 (no) | 1998-12-14 |
Family
ID=26299395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO923128A NO304406B1 (no) | 1991-08-12 | 1992-08-11 | Preparat med regulert frigivelse og kapsel omfattende dette |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US5670172A (de) |
| EP (1) | EP0527637B1 (de) |
| JP (1) | JP3019235B2 (de) |
| KR (1) | KR100221695B1 (de) |
| CN (1) | CN1052398C (de) |
| AT (1) | ATE165513T1 (de) |
| AU (1) | AU651715B2 (de) |
| CA (1) | CA2075356A1 (de) |
| DE (1) | DE69225278D1 (de) |
| ES (1) | ES2115643T3 (de) |
| FI (1) | FI923582A (de) |
| IL (1) | IL102778A (de) |
| NO (1) | NO304406B1 (de) |
| PH (1) | PH31288A (de) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
| FR2702160B1 (fr) * | 1993-03-02 | 1995-06-02 | Biovecteurs As | Vecteurs particulaires synthétiques et procédé de préparation. |
| SE9301220D0 (sv) * | 1993-04-14 | 1993-04-14 | Kabi Pharmacia Ab | Manufacturing matrices |
| US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
| US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
| GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
| US5914134A (en) * | 1997-01-27 | 1999-06-22 | Wockhardt Europe Limited | Process for the pulsatile delivery of diltiazem HCL and product produced thereby |
| US7060734B1 (en) | 1997-09-09 | 2006-06-13 | Alza Corporation | Pharmaceutical coating composition and method of use |
| DE69827650T2 (de) * | 1997-09-09 | 2005-11-03 | Alza Corp., Mountain View | Pharmazeutische Überzugszusammensetzung und Verfahren zum Beschichten einer Dosierungsform hiermit |
| US5891845A (en) * | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
| JP2001526229A (ja) * | 1997-12-22 | 2001-12-18 | ユーロ−セルティーク，エス．エイ． | オピオイド投薬剤形の乱用を防止する方法 |
| HU1500214D0 (hu) | 1997-12-22 | 2002-03-28 | Euro Celtique Sa | Opioid agonista és antagonista hatóanyagot tartalmazó gyógyszerkészítmény |
| US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
| US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
| US6432448B1 (en) | 1999-02-08 | 2002-08-13 | Fmc Corporation | Edible coating composition |
| US6723342B1 (en) | 1999-02-08 | 2004-04-20 | Fmc Corporation | Edible coating composition |
| US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
| MXPA01011613A (es) | 1999-05-14 | 2003-10-14 | Nereus Pharmaceuticals Inc | Nuevos moduladores de interleucina-1 y factor-alfa de necrosis tumoral, sistesis de dichos moduladores y metodos de utilizar dichos moduladores. |
| GB9913979D0 (en) | 1999-06-17 | 1999-08-18 | Univ Wales Medicine | Spheroid preparation |
| US6500462B1 (en) | 1999-10-29 | 2002-12-31 | Fmc Corporation | Edible MCC/PGA coating composition |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| AU764453B2 (en) | 1999-10-29 | 2003-08-21 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US20060153914A1 (en) * | 1999-12-10 | 2006-07-13 | Biovail Laboratories International S.R.L. | Chronotherapeutic diltiazem formulations and the administration thereof |
| US7108866B1 (en) | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
| OA12215A (en) | 2000-02-08 | 2006-05-09 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations. |
| CA2400642A1 (en) * | 2000-02-23 | 2001-08-30 | Vertex Pharmaceuticals (San Diego) Llc | Modified fluorescent proteins |
| US6852031B1 (en) * | 2000-11-22 | 2005-02-08 | Igt | EZ pay smart card and tickets system |
| US6635277B2 (en) | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
| GB0025208D0 (en) * | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| CN101317825A (zh) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
| US7144723B2 (en) * | 2000-11-16 | 2006-12-05 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product discovery |
| IL155959A0 (en) | 2000-11-28 | 2003-12-23 | Fmc Corp | Edible pga (propylene glycol alginate) coating composition |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| ES2361148T3 (es) | 2001-05-11 | 2011-06-14 | Endo Pharmaceuticals Inc. | Forma de dosificación de opioides de liberación controlada resistente al abuso. |
| DE60230632D1 (de) | 2001-07-18 | 2009-02-12 | Euro Celtique Sa | Pharmazeutische kombinationen von oxycodon und naloxon |
| IS7142A (is) | 2001-08-06 | 2004-02-05 | Euroceltique S.A. | Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi |
| AU2002324624A1 (en) * | 2001-08-06 | 2003-02-24 | Euro-Celtique S.A. | Sequestered antagonist formulations |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| EP2425823A1 (de) | 2002-04-05 | 2012-03-07 | Euro-Celtique S.A. | Pharmazeutische Zubereitung mit Oxycodon und Naloxon |
| US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
| EP1551372B8 (de) * | 2002-09-20 | 2018-08-01 | Alpharma Pharmaceuticals LLC | Sequestrier-untereinheit und relevante zusammensetzungen und verfahren |
| US7112581B2 (en) * | 2002-09-27 | 2006-09-26 | Nereus Pharmaceuticals, Inc. | Macrocyclic lactams |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| US20040208932A1 (en) * | 2003-04-17 | 2004-10-21 | Ramachandran Thembalath | Stabilized paroxetine hydrochloride formulation |
| TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
| US8217072B2 (en) * | 2003-06-20 | 2012-07-10 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
| DE602004031614D1 (de) * | 2003-06-20 | 2011-04-14 | Nereus Pharmaceuticals Inc | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs |
| CA2445420A1 (en) * | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
| US7727752B2 (en) | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
| US7619059B2 (en) * | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
| JP2007505315A (ja) * | 2003-09-12 | 2007-03-08 | インヴィトロジェン コーポレーション | 多重結合および活性アッセイ |
| US7166634B2 (en) * | 2004-01-23 | 2007-01-23 | Nereus Pharmaceuticals, Inc. | Bis-indole pyrroles useful as antimicrobials agents |
| US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
| JP2007535559A (ja) | 2004-04-30 | 2007-12-06 | ネレアス ファーマシューティカルズ インコーポレイテッド | ［３．２．０］複素環式化合物及びその使用法 |
| EP1604666A1 (de) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| EP1827385B1 (de) | 2004-11-23 | 2013-03-27 | Adamas Pharmaceuticals, Inc. | Pharmazeutische zusammensetzung enthaltend memantin in verzögerter freisetzungs-form zur behandlung von dementia |
| EP2623099A1 (de) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Zusammensetzung und Verfahren zur Behandlung neurologischer Erkrankungen |
| KR101282191B1 (ko) * | 2004-12-03 | 2013-07-08 | 다나-파버 캔서 인스티튜트 인크. | 신생물성 질환을 치료하는 조성물 및 방법 |
| EP1702558A1 (de) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Verfahren und Vorrichtung zur Darmtätigkeitserfassung |
| CA2603031A1 (en) * | 2005-03-31 | 2006-10-05 | Rafael Armament Development Authority Ltd. | Apparatus for treating particles and liquids by ultrasound |
| PL1874282T3 (pl) | 2005-04-06 | 2011-04-29 | Adamas Pharmaceuticals Inc | Sposoby i kompozycje do leczenia zaburzeń OUN |
| CA2613366A1 (en) | 2005-07-21 | 2007-02-08 | Nereus Pharmaceuticals, Inc. | Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators |
| EP2526932B1 (de) | 2006-06-19 | 2017-06-07 | Alpharma Pharmaceuticals LLC | Pharmazeutische Zusammensetzung |
| EP2049087A2 (de) * | 2006-07-21 | 2009-04-22 | LAB International SRL | Hydrophiles missbrauchssicheres ausgabesystem |
| EP1920767A1 (de) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Schmelzverarbeitete Darreichungsform mit Imatinib |
| WO2008095195A2 (en) * | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
| US20090017167A1 (en) * | 2007-07-11 | 2009-01-15 | Herbalife International Inc. | Mixture and beverage made therefrom for protecting cellular hydration |
| US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
| US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| US20100266645A1 (en) * | 2007-12-17 | 2010-10-21 | Alfred Liang | Pharmaceutical compositions |
| AU2008338207A1 (en) * | 2007-12-17 | 2009-06-25 | Labopharm (Barbados) Limited | Misuse preventative, controlled release formulation |
| AU2009246467A1 (en) * | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Salinosporamide derivatives as proteasome inhibitors |
| EP2317991B1 (de) * | 2008-07-07 | 2017-05-03 | Euro-Celtique S.A. | Verwendung von opioid-antagonisten zur behandlung von harnverhalt |
| MX347106B (es) | 2009-03-10 | 2017-04-12 | Euro-Celtique S A * | Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona. |
| EP3132793A1 (de) | 2009-12-02 | 2017-02-22 | Adamas Pharmaceuticals, Inc. | Amantadinzusammensetzungen und verfahren zur verwendung |
| CA2835293C (en) | 2011-06-08 | 2020-08-18 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| ITFI20110172A1 (it) * | 2011-08-08 | 2013-02-09 | Valpharma Sa | Formulazione multiparticolata a rilascio modificato di diltiazem hcl. |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| CN105517551A (zh) | 2013-07-23 | 2016-04-20 | 欧洲凯尔特公司 | 用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合 |
| EP3628640B1 (de) | 2014-09-02 | 2023-08-09 | Hub Therapeutics | Verfahren zur herstellung eines deuterierten oder eines nichtdeuterierten moleküls und pharmazeutische formulierungen zur behandlung |
| WO2016057563A1 (en) | 2014-10-08 | 2016-04-14 | Pacific Northwest Diabetes Research Institute | Methods and compositions for increasing the potency of antifungal agents |
| EP3397253A1 (de) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals, Inc. | Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit krämpfen |
| WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
| MX2020010036A (es) | 2018-03-28 | 2021-03-02 | Herbalife Int Of America Inc | Acetilacion de polisacaridos. |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456628A (en) * | 1981-01-07 | 1984-06-26 | Bauer Kurt H | Process for film-coating a particulate solid, and emulsions for conducting the process |
| DK152744C (da) * | 1982-08-13 | 1988-10-31 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat |
| US4898729A (en) * | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| US5002776A (en) * | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
| US4917899A (en) * | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4894240A (en) * | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
| IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
| DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
| US4643731A (en) * | 1985-08-16 | 1987-02-17 | Alza Corporation | Means for providing instant agent from agent dispensing system |
| JPS62103012A (ja) * | 1985-10-23 | 1987-05-13 | Eisai Co Ltd | 多重顆粒 |
| IT1200217B (it) * | 1986-09-30 | 1989-01-05 | Valducci Roberto | Membrana per uso farmaceutico ed industriale |
| DE3709188A1 (de) * | 1987-03-20 | 1988-09-29 | Mannesmann Ag | Ausgiessrohr fuer metallurgische gefaesse |
| GB8707421D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
| US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
| CA1323833C (en) * | 1987-04-28 | 1993-11-02 | Yatindra M. Joshi | Pharmaceutical compositions in the form of beadlets and method |
| BE1000794A4 (nl) * | 1987-07-30 | 1989-04-04 | Schelde Delta Bv Met Beperkte | Werkwijze voor het bij chemische processen immobiliseren van komponenten in een fluidumstroom, en inrichtingen die deze werkwijze toepassen. |
| US4814181A (en) * | 1987-09-03 | 1989-03-21 | Alza Corporation | Dosage form comprising fast agent delivery followed by slow agent delivery |
| DE3856555T2 (de) * | 1987-10-16 | 2004-04-29 | Elan Corp. Plc | Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption |
| US5219621A (en) * | 1987-10-16 | 1993-06-15 | Elan Corporation, Plc | Methods of treatment with diltiazem formulations |
| IL88083A (en) * | 1987-11-06 | 1992-11-15 | Tanabe Seiyaku Co | Controlled release pharmaceutical dosage form and its preparation |
| DE3739779A1 (de) * | 1987-11-24 | 1989-06-08 | Beiersdorf Ag | Pharmazeutische praeparate |
| FR2623714B1 (fr) * | 1987-11-26 | 1990-04-20 | Ethypharm Sa | Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu |
| FR2624732B1 (fr) * | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
| JP2643222B2 (ja) * | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | 多重層顆粒 |
| GB8805695D0 (en) * | 1988-03-10 | 1988-04-07 | Nycomed As | Enteric coated spheroidal granules |
| FI101344B1 (fi) * | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta |
| FR2630647B1 (fr) * | 1988-04-27 | 1991-08-16 | Sanofi Sa | Microbilles de diltiazem, leur procede de fabrication et compositions pharmaceutiques a liberation prolongee les contenant |
| KR900701255A (ko) * | 1988-11-30 | 1990-12-01 | 스테이너 브이.캔스타드 | 서방성 딜티아젬 제제 |
| SE506179C2 (sv) * | 1989-01-23 | 1997-11-17 | Ciba Geigy Ag | Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum |
| SE8902699D0 (sv) * | 1989-08-09 | 1989-08-09 | Lejus Medical Ab | Diltiazem containing pharmaceutical compositios |
| JPH0674206B2 (ja) * | 1989-12-28 | 1994-09-21 | 田辺製薬株式会社 | 放出制御型製剤およびその製法 |
| IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| US5286497A (en) * | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
| ZA923474B (en) * | 1991-05-20 | 1993-01-27 | Marion Merrell Dow Inc | Diltiazem formulation |
-
1992
- 1992-08-04 KR KR1019920013984A patent/KR100221695B1/ko not_active IP Right Cessation
- 1992-08-05 CA CA002075356A patent/CA2075356A1/en not_active Abandoned
- 1992-08-06 AU AU20880/92A patent/AU651715B2/en not_active Expired
- 1992-08-10 IL IL10277892A patent/IL102778A/en not_active IP Right Cessation
- 1992-08-10 JP JP4234295A patent/JP3019235B2/ja not_active Expired - Lifetime
- 1992-08-10 PH PH44791A patent/PH31288A/en unknown
- 1992-08-11 ES ES92307333T patent/ES2115643T3/es not_active Expired - Lifetime
- 1992-08-11 EP EP92307333A patent/EP0527637B1/de not_active Expired - Lifetime
- 1992-08-11 AT AT92307333T patent/ATE165513T1/de active
- 1992-08-11 FI FI923582A patent/FI923582A/fi unknown
- 1992-08-11 DE DE69225278T patent/DE69225278D1/de not_active Expired - Lifetime
- 1992-08-11 NO NO923128A patent/NO304406B1/no not_active IP Right Cessation
- 1992-08-12 CN CN92105698A patent/CN1052398C/zh not_active Expired - Lifetime
-
1995
- 1995-04-21 US US08/426,065 patent/US5670172A/en not_active Expired - Lifetime
-
1996
- 1996-06-18 US US08/666,636 patent/US5601845A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE165513T1 (de) | 1998-05-15 |
| ES2115643T3 (es) | 1998-07-01 |
| FI923582A (fi) | 1993-02-13 |
| IL102778A (en) | 1999-05-09 |
| AU2088092A (en) | 1993-02-18 |
| DE69225278D1 (de) | 1998-06-04 |
| JP3019235B2 (ja) | 2000-03-13 |
| CN1052398C (zh) | 2000-05-17 |
| FI923582A0 (fi) | 1992-08-11 |
| US5670172A (en) | 1997-09-23 |
| EP0527637B1 (de) | 1998-04-29 |
| NO923128D0 (no) | 1992-08-11 |
| JPH05201867A (ja) | 1993-08-10 |
| CA2075356A1 (en) | 1993-02-13 |
| CN1069408A (zh) | 1993-03-03 |
| IL102778A0 (en) | 1993-01-31 |
| NO923128L (no) | 1993-02-15 |
| AU651715B2 (en) | 1994-07-28 |
| KR930003906A (ko) | 1993-03-22 |
| KR100221695B1 (ko) | 1999-09-15 |
| US5601845A (en) | 1997-02-11 |
| PH31288A (en) | 1998-07-06 |
| EP0527637A1 (de) | 1993-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO304406B1 (no) | Preparat med regulert frigivelse og kapsel omfattende dette | |
| US5508044A (en) | Diltiazem pharmaceutical spheroid formulation | |
| JP4749639B2 (ja) | 味がマスクされ、活性成分を即時放出する、被覆された顆粒の製造方法 | |
| KR100514467B1 (ko) | 신속 붕괴 펠릿 | |
| JP2542122B2 (ja) | 球状核、球形顆粒およびその製造方法 | |
| ES2226886T3 (es) | Forma de administracion de accion retardada que contiene sacarinato de tramadol. | |
| KR20010074914A (ko) | 오메프라졸 제형 | |
| JP2789525B2 (ja) | 調節放出性物品 | |
| JP2000212075A (ja) | 貯蔵安定な放出様相を有する徐放性トラマド―ル調合物及びその製造方法 | |
| CN1882321B (zh) | 包含盐酸文拉法辛的小丸 | |
| ZA200103630B (en) | Particles coated with granulated crystalline ibuprofen. | |
| WO2006130702A2 (en) | Modified release formulations of antihypertensive drugs | |
| JPS58116414A (ja) | ニカルジピン持続性製剤用球形顆粒およびその製造法 | |
| US20070092568A1 (en) | Galantamine compositions | |
| CN114929207A (zh) | 利奥西呱的调节释放型药物组合物 | |
| GB2258613A (en) | Pharmaceutical diltiazem spheroid formulation | |
| US20130156934A1 (en) | Microcapsules by coacervation containing a pharmaceutical incorporated in the coating polymer | |
| GB2258810A (en) | Pharmaceutical combination formulation of diltiazem and hydrochlorothiazide | |
| WO2008062426A2 (en) | Formulation of benzazepine derivatives | |
| JP2021046379A (ja) | ラメルテオンの安定な製剤及び製剤の安定化方法 | |
| JP2021046380A (ja) | ラメルテオン含有被覆製剤 | |
| WO2016117642A1 (ja) | フィルム製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |